Marie Stopes International is a company limited by guarantee, incorporated and registered in England and Wales, and is also registered as a charity.
In pursuing its mission of 'children by choice, not chance' and promoting reproductive health choice across the world, it provides services in 37 countries through its branches and other not for profit companies and organisations which form part of its global Partnership.
From its international support office in central London, it supports and oversees the impact of its members by setting the strategy, standards and policies for the global partnership. It also provides technical assistance, research and monitoring and promotes and fundraises for the global Partnership. In keeping with its mission, it focuses on creating the conditions that enable the provision of quality services, which are sustainable and reach as many women and men as possible.
It’s UK division has separate offices and management structure, and provides abortion and other reproductive and sexual health services in the UK through a network of clinics.
The Marie Stopes International Board of Trustees makes decisions on major issues facing the partnership including in the areas of: strategic direction, clinical practices, polices and processes, financial management and institutional integrity. The Board also has various subcommittees, for example the Audit Committee and Global Quality Governance Committee, that focus on high priority areas.
The Executive Team, based in the London Support Office, is responsible for implementing strategy and the day-to-day operations which enable the Partnership to meet its mission and goals. The Executive Team is led by the Chief Executive Officer who reports to the Board of Trustees.
The Board of Trustees is made up of individuals who are leaders in their field, committed to the organisation’s mission. They bring skill, diversity, energy, and experience to Marie Stopes International. Their backgrounds include senior level experience in: the commercial health sector; clinical and teaching experience in women’s reproductive health; leadership in the charity sector; business; government; and advocacy.
You can find out more about our Board members and Executive Team on the People page.
The quality of our services is fundamental to the safety and wellbeing of every single one of our clients. With this in mind we set rigorous standards and have the following systems in place to check and maintain consistently high quality across all our international programmes.
QTA is a quality audit that covers a sample of service locations and teams within each country programme once a year. This is conducted by Global Medical Development Team (MDT) members, trained clinical quality staff from other programmes, or MDT-approved external consultants.
A quality audit covering a sample of service locations and teams within each country programme once a year. This is conducted by MDT, trained clinical quality staff from another programme, or MDT-approved external consultants
A ‘QTA-like’ clinical quality audit that several selected country programmes receive each year. These are carried out by Global MDT members in programmes that did not receive an external QTA by Global MDT members that year.
A senior leadership team within each country programme, led by the head of clinical services and including the country director. The Medical Advisory Team (MAT) in each country programme meets once every quarter to discuss key issues related to clinical quality and client safety. The meetings follow a standard agenda and the minutes are sent to the Global MDT.
A standard report that captures key clinical quality and clinical governance indicators that each country programme is required to submit quarterly. The reports are compiled by the clinical service leads of each country programme and are submitted through International Operations reporting systems. The minutes of the last MAT meeting is submitted together with these reports.
All country programmes service providers are expected to report clinical incidents in line with a standard reporting system. Incidents are categorised into ‘red’, ‘amber’, and ‘green’ based on severity. ‘Red’ or critical incidents are reported to the Medical Director within 24 hours of the incident.
‘Amber’ and ‘green’ incidents are reported to the senior management of each programme. Critical incidents are reviewed by a panel of Global MDT members and lessons shared across the partnership. ‘Amber’ and ‘green’ incidents are handled at country programme level. Incidents are a key item discussed during the MAT meetings.
All country programmes report product-related incidents to MDT. These incidents are investigated by the senior pharmaceutical adviser in collaboration with clinical leads and other MDT members. Corrective measures are taken and reporting to manufacturers done where needed. Learning is shared across the partnership.
This is a system that calculates estimated clinical risk within different channels based on service types provided, service numbers, and selected control indicators. With no extra data burden to country programmes, the system is able to highlight higher-risk channels by country, and allows MDT and Operations to recognise and mitigate potential sources of clinical risk.
A product quality assurance tool that allows Marie Stopes International to confirm that ‘Key-SRH’ commodities in country programmes come from quality sources of established quality. The system requires country programmes to input information on selected drugs and other items on a regular basis.
These tools are expected in all country programmes:
You can find out more about our Global Medical Development Team on the People page.